Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Terns Pharmaceuticals stock | $9.94
Learn how to easily invest in Terns Pharmaceuticals stock.
Terns Pharmaceuticals Inc is a biotechnology business based in the US. Terns Pharmaceuticals shares (TERN) are listed on the NASDAQ and all prices are listed in US Dollars. Terns Pharmaceuticals employs 30 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Terns Pharmaceuticals
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – TERN – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Terns Pharmaceuticals stock price (NASDAQ: TERN)Use our graph to track the performance of TERN stocks over time.
Terns Pharmaceuticals shares at a glance
|Latest market close||$9.94|
|52-week range||$6.92 - $28.36|
|50-day moving average||$11.29|
|200-day moving average||$13.82|
|Wall St. target price||$20.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.39|
Buy Terns Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Terns Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Terns Pharmaceuticals price performance over time
|1 week (2021-10-08)||-3.59%|
|1 month (2021-09-15)||-7.19%|
|3 months (2021-07-15)||12.44%|
|6 months (2021-04-15)||-43.87%|
|1 year (2020-10-11)||N/A|
|2 years (2019-10-11)||N/A|
|3 years (2018-10-11)||N/A|
|5 years (2016-10-11)||N/A|
Terns Pharmaceuticals financials
|Gross profit TTM||$0|
|Return on assets TTM||-39.83%|
|Return on equity TTM||-68.73%|
|Market capitalisation||$259.1 million|
TTM: trailing 12 months
Shorting Terns Pharmaceuticals shares
There are currently 688,997 Terns Pharmaceuticals shares held short by investors – that's known as Terns Pharmaceuticals's "short interest". This figure is 2.4% up from 672,985 last month.
There are a few different ways that this level of interest in shorting Terns Pharmaceuticals shares can be evaluated.
Terns Pharmaceuticals's "short interest ratio" (SIR)
Terns Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Terns Pharmaceuticals shares currently shorted divided by the average quantity of Terns Pharmaceuticals shares traded daily (recently around 64033.178438662). Terns Pharmaceuticals's SIR currently stands at 10.76. In other words for every 100,000 Terns Pharmaceuticals shares traded daily on the market, roughly 10760 shares are currently held short.
To gain some more context, you can compare Terns Pharmaceuticals's short interest ratio against those of similar companies.
However Terns Pharmaceuticals's short interest can also be evaluated against the total number of Terns Pharmaceuticals shares, or, against the total number of tradable Terns Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Terns Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Terns Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.07% of the tradable shares (for every 100,000 tradable Terns Pharmaceuticals shares, roughly 70 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Terns Pharmaceuticals.
Find out more about how you can short Terns Pharmaceuticals stock.
Terns Pharmaceuticals share dividends
We're not expecting Terns Pharmaceuticals to pay a dividend over the next 12 months.
Have Terns Pharmaceuticals's shares ever split?
Terns Pharmaceuticals's shares were split on a 1000:50 basis on 3 November 2013. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1000 shares. This wouldn't directly have changed the overall worth of your Terns Pharmaceuticals shares – just the quantity. However, indirectly, the new 95% lower share price could have impacted the market appetite for Terns Pharmaceuticals shares which in turn could have impacted Terns Pharmaceuticals's share price.
Terns Pharmaceuticals overview
Terns Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase I clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and GLP-1R, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to address metabolic processes involved in the pathogenesis of NASH. Terns Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Foster City, California. .
Terns Pharmaceuticals in the news
Terns Pharmaceuticals to Present at H.C. Wainwright 5th Annual NASH Investor Conference
Terns Pharmaceuticals : to Present at H.C. Wainwright 5th Annual NASH Investor Conference
Terns Pharmaceuticals to Present at H.C. Wainwright 5th Annual NASH Investor Conference
Frequently asked questionsWhat percentage of Terns Pharmaceuticals is owned by insiders or institutions?
Currently 7.77% of Terns Pharmaceuticals shares are held by insiders and 85.259% by institutions. How many people work for Terns Pharmaceuticals?
Latest data suggests 30 work at Terns Pharmaceuticals. When does the fiscal year end for Terns Pharmaceuticals?
Terns Pharmaceuticals's fiscal year ends in December. Where is Terns Pharmaceuticals based?
Terns Pharmaceuticals's address is: 1065 East Hillsdale Boulevard, Foster City, CA, United States, 94404 What is Terns Pharmaceuticals's ISIN number?
Terns Pharmaceuticals's international securities identification number is: US8808811074
More guides on Finder
How to buy Aura Biosciences (AURA) stock when it goes public
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
How to buy Claros Mortgage Trust (CMTG) stock when it goes public
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
How to buy Evotec SE (EVO) stock when it goes public
Everything we know about the Evotec SE IPO, plus information on how to buy in.
How to buy Delimobil Holding SA (DMOB) stock when it goes public
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
How to buy Blue Water Vaccines (BWV) stock when it goes public
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
How to buy Sonendo (SONX) stock when it goes public
Everything we know about the Sonendo IPO, plus information on how to buy in.
How to buy FlexEnergy Green Solutions (FLXE) stock when it goes public
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
How to buy Stran & Company (STRN) stock when it goes public
Everything we know about the Stran & Company IPO, plus information on how to buy in.
How to buy Kidpik Corp (PIK) stock when it goes public
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
How to buy Nuvectis Pharma (NVCT) stock when it goes public
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
Ask an Expert